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Abstract
Background: The General Transcription Apparatus (GTA) comprises more than one hundred
proteins, including RNA Polymerases, GTFs, TAFs, Mediator, and cofactors such as heterodimeric
NC2. This complexity contrasts with the simple mechanical role that these proteins are believed
to perform and suggests a still uncharacterized participation to important biological functions, such
as the control of cell proliferation.
Results:  To verify our hypothesis, we analyzed the involvement in Neuroblastoma (NB)
pathogenesis of GTA genes localized at 1p, one of NB critical regions: through RT-PCR of fifty eight
NB biopsies, we demonstrated the statistically significant reduction of the mRNA for NC2β
(localized at 1p22.1) in 74% of samples (p = 0.0039). Transcripts from TAF13 and TAF12 (mapping
at 1p13.3 and 1p35.3, respectively) were also reduced, whereas we didn't detect any quantitative
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alteration of the mRNAs from GTF2B and NC2α (localized at 1p22-p21 and 11q13.3, respectively).
We confirmed these data by comparing tumour and constitutional DNA: most NB samples with
diminished levels of NC2β mRNA had also genomic deletions at the corresponding locus.
Conclusion: Our data show that NC2β is specifically involved in NB pathogenesis and may be
considered a new NB biomarker: accordingly, we suggest that NC2β, and possibly other GTA
members, are physiologically involved in the control of cell proliferation. Finally, our studies
unearth complex selective mechanisms within NB cells.
Background
Transcription initiation, the most important and regu-
lated event along the pathway connecting genotype to
phenotype, is governed by the General Transcription
Apparatus (GTA): GTA proteins constitute the PreInitia-
tion Complex (PIC) and guide its assembly [1-3]. Class II
PIC, larger than 2 MDa, comprises more than fifty differ-
ent polypeptides, including RNA polymerase II, GTFs,
Mediator [4-6]. GTF2D consists of the TATA Box – Bind-
ing Protein (TBP) and TBP – Associated Factors (TAFs), a
group of evolutionarily conserved proteins that partici-
pate in determining the state of chromatin, contribute to
promoter recognition, serve as coactivators, and post-
translationally modify other GTA proteins to facilitate PIC
assembly and transcription initiation [1,5]. Its DNA bind-
ing activity is regulated by positive and negative cofactors
such as heterodimeric NC2 (also named Dr1/Drap 1),
comprised of α- and β-type subunits [7,8]. The molecular
actions of GTA proteins were clarified through an exten-
sive series of studies [1-3,6,9]. On the other hand, only
scanty success was obtained in identifying their biological
functions as well as in verifying their involvement in
genetic pathology, including tumorigenesis [10,11]. We
examined the involvement of GTA proteins in the patho-
genesis of Neuroblastoma (NB), exploiting our data and
those from the literature on the genomics of GTA (see
Additional file 1; reviewed in ref. [12]) to perform the
positional and functional gene candidate approach. NB is
a group of early childhood tumours with a complex
molecular pathogenesis [13,14]. It is generally believed
that the abnormally proliferating cell in all types of NB is
the neuroblast, a fleeting stem cell that transiently appears
during the early stages of mammalian development [15].
NB clinical phenotype is remarkably heterogeneous, rang-
ing from spontaneous regression to restless progression
[14,16]. This variability is associated to a high genetic het-
erogeneity. The most important genomic alterations in
NB are interstitial deletions at 1p, 11q, 17q, and MYCN
amplification [14,17]. NB molecular phenotype is charac-
terized by the altered expression of a plethora of genes
belonging to different Gene Ontology categories: all of
them are potential NB biomarkers [14,18]. Our analysis
was initially focused on human chromosome 1 short arm,
where one or more NB master genes are thought to reside
[17,19]. In this region, we had previously mapped the
genes encoding TAF13, GTF2B, NC2β, TAF12 to 1p13.3,
1p21-p22, 1p22.1, 1p35.3, respectively [20-22].
Methods
NB samples
NB patients were 30 males and 28 females. Tumour pri-
mary site was adrenal in 33 patients, abdominal nonadre-
nal in 18, thoracic in 5, cervical in 2. Tumours were
classified according to the International Neuroblastoma
Pathology Classification (INPC) [23]. The final patho-
logic diagnosis fulfilled the International Criteria for Neu-
roblastoma Diagnosis [13]. Patients were staged
according to the International Neuroblastoma Staging
Table 1: Primers and RT-PCR conditions for expression analysis
PCR primers RT-PCR conditions
NC2β fw: 5' CGATGATGATCTCACTATCC 3'
NC2β rev: 5' GTTGCTGTCTAGCTTTTGC 3'
50°C 30 min; (94°C 60 sec, 47°C 90 sec, 72°C 2 min) 25×; 72°C 10 min.
NC2α fw: 5' AGACGGACGAAGAGATTGG 3'
NC2α rev: 5' CATGTCGGGAACAGATGC 3'
50°C 30 min; (94°C 60 sec, 53°C 90 sec, 72°C 2 min) 27×; 72°C 10 min.
GTF2B fw: 5' AGAAGAGCCTGAAGGGAAGAGC 3'
GTF2B rev: 5' CAGCAACACCAGCAATATCTCC 3'
50°C 30 min; (94°C 60 sec, 50°C 90 sec, 72°C 2 min) 27×; 72°C 10 min.
TAF12 fw: 5' GAGCAGTTGGATGAAGATGTGG 3'
TAF12 rev: 5' TGAGATGGCAGGGAAAAGG 3'
50°C 30 min; (94°C 60 sec, 57°C 90 sec, 72°C 2 min) 26×; 72°C 10 min.
TAF13 fw: 5' GCAGATGAGGAAGAAGACC 3'
TAF13 rev: 5' TATCTTCAACTTGTACTCGACC 3'
50°C 30 min; (94°C 60 sec, 54°C 90 sec, 72°C 2 min) 27×; 72°C 10 min.
β actin fw: 5' GTGCCCATCTATGAGGGTTACG 3'
β actin rev: 5' TGATCCACATCTGCTGGAAGG 3'
50°C 30 min; (94°C 60 sec, 46°C 90 sec, 72°C 2 min) 25×; 72°C 10 min.Molecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
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System: 12 patients were at stage I, 8 at stage II, 6 at stage
III, 23 at stage IV, and 9 at stage IVS. The clinical and
molecular characteristics of the patients are reported (see
Additional file 2).
Expression of TAF13, GTF2B, NC2α, TAF12, NC2β
Total RNA from NB biopsies and from peripheral blood of
ten normal controls (BL) was isolated according to our
published protocol [12]. Primers were designed with the
OMIGA 2.0 software (Oxford Molecular) by using as tem-
plate the published sequences of Homo sapiens genes: their
sequence and corresponding RT-PCR conditions are
shown in Table 1. Transcript reduction was determined by
calculating the arithmetic mean of the densitometric val-
ues of all samples and using this value as cut-off: only dif-
ferences that were at least threefold were considered
significant to this study.
Genomics of TAF13, NC2β, TAF12 in NB samples
Microsatellite polymorphic markers were selected from
the Marshfield map [24] as close as possible to the 5' and
3' ends of TAF13, GTF2B, NC2β, TAF12 (Table 2, Figure
1). Primers for sequencing were designed with the same
software; their sequence was: NC2βS: gtgggtgggggaagg;
TAF12S: agggtgtatttatatatagttta; TAF13S: tcccaactaattacac-
tact. PCR was performed according to standard protocols
(Invitrogen). Tumour and constitutional (blood) DNA (3
to 5 ng depending on primers efficiency) was amplified
with a Master Cycler Gradient (Eppendorf). Forward
primers were labeled at their 5' with the fluorochromes
Tamra, Joe or 6-Fam (MWG Biotech). Amplified DNA was
loaded on ABI PRISM™ 310 Genetic Analyzer (Applied
Biosystems): the results were analyzed with ABI PRISM
310 GeneScan 3.1 software. GI was determined by com-
paring the allelic ratios between constitutional and
tumour DNA in heterozygous samples [25]. Theoretically
Table 2: Microsatellite polymorphic markers used for GI analysis
Locus Marker Chromos
omal 
Position
Heterozygosity PCR primers Size (bp) PCR conditions
NC2β 5' D1S2776 92982656 
– 
92982869
0.75 5' AATGCCTGTCTTTATCCCTG 3'
5' AATGTAAGAGAAATGCCCCT 3'
196 – 212 95°C 10 min (95°C 30 sec, 
52°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
NC2β 3' D1S2813 95036107 
– 
95036299
0.72 5' CTTTTGACTCACTGGAAGACAT 3'
5' CCCCACCGTATCTGGTAT 3'
185 – 205 95°C 10 min (95°C 30 sec, 
55°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
NC2β 3' D1S2664 95718483 
– 
95718723
0.73 5' CAGCCCACAGAATAACACTG 3'
5' TTCATGCTATGATTTTCCGC 3'
202 – 254 95°C 10 min (95°C 30 sec, 
54°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
TAF12 5' D1S2787 27999563 
– 
27999728
0.76 5' TTTAACCCTGGAAGGTTGAG 3'
5' ACAGGACAATGCTGTCAGTATG 3'
137 – 167 95°C 10 min (95°C 30 sec, 
52°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
TAF12 3' G60315 30205319 
– 
30205625
- 5' AGCTGAGTCAGGGAAACCCATT 3'
5' TGTGCTCTTCAATGTGTTAGGGA 3'
307 – 340 95°C 10 min (95°C 30 sec, 
56°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
TAF13 5' D1S2778 108849441 
– 
108849609
0.66 5' CACAGTTAAATTGCATTTCC 3'
5' GCTCACCATAAACAAGAGG 3'
161 – 173 95°C 10 min (95°C 30 sec, 
50°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
TAF13 3' D1S221 110103235 
– 
110103467
0.75 5' CCTACAACTCCATCCTGTCC 3'
5' GTCTTAAGTCGCTCTGCCTG 3'
215 – 225 95°C 10 min (95°C 30 sec, 
56°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
NC2α 3' D11S1889 67069719 
– 
67069901
0.67 5' AGCTGGACTCTCACAGAATG 3'
5'CAAGAGGCTGGTAGAAGGTG3'
183 – 207 95°C 10 min (95°C 30 sec, 
60°C 30 sec, 72°C 30 sec) 
30×; 72°C 10 min
NC2α 3' D11S4178 67945684 
– 
67945935
0.69 5' CAGGCCCAGTCTCTTG 3'
5' CGTGTCCAGATGAAAGTG 3'
237 – 260 95°C 10 min (95°C 30 sec, 
52°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min.
GTF2B 5' D1S2856 82130207 
– 
82130465
0.5 5' AGCTCTGTGACATTGGATAA 3'
5' CAGAACATAATAAGTGTGGCTA 3'
257 – 263 95°C 10 min (95°C 30 sec, 
53°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min.
GTF2B 5' D1S454 82540746 
– 
82540872
0.56 5' TGTTAGTTCCTGTTCTTGGTGA 3'
5' TTCCCTGGAAACAACCATAA 3'
155 – 163 95°C 10 min (95°C 30 sec, 
58°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 min
GTF2B 3' D1S435 91331437 
– 
91331556
0.73 5' GGCCACATGGGAATTTTCT 3'
5' AGCAGTTCAAGGCCACAGT 3'
157 – 177 95°C 10 min (95°C 30 sec, 
55°C 75 sec, 72°C 30 sec) 
30×; 72°C 10 minMolecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
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QGI = 0 expresses the total loss of one allele and QGI = 1
indicates the normal allele ratio. We refer to Genomic
Imbalance when QGI ≤ 0.5.
Methylation analysis
The location of CpG islands in the bone fide promoter
regions of NC2β, TAF12 and TAF13 was determined with
the CpGPLOT software [26], after masking the repeated
sequences with Repeat Masker [27]. The NB samples and
cell lines analyzed are listed in Additional file 3. Quanti-
tative methylation analysis was performed by pyrose-
quencing with a SPQ 96MA instrument (Biotage,
Uppsala, Sweden) [28]. Pyrosequencing is a sequencing
by synthesis-analysis of short genomic sequences that is
ideally suited for SNP analysis. In this respect, DNA meth-
ylation can be considered a special case of polymorphism
revealed by the bisulfite chemical reaction that converts
only the unmethylated Cs into Ts [29]. 2 μl of bisulfite
modified DNA were amplified with primers designed
with the Assay Design Software for Pyrosequencing
(Biotage, Uppsala, Sweden) to amplify target sequences
independently of their methylation status. The amplified
targets were then subjected to pyrosequencing analysis.
Primers sequences were: NC2βF: gtttttgtgaaggaatggga;
NC2βR: tcaaatttccccctccct (amplicon size: 153 bp, Ta
58°C); TAF12F: aagagtaagttgtagggtgtattt; TAF12R:
acaaaaactaccccaataaaa (amplicon size: 214 bp, Ta 58°C);
TAF13F: ggtttttttttttagagattgt; TAF13R: aaaatcttcttcctcatc-
tactacca (amplicon size: 208 bp, Ta 58.5°C). Sequencing
reactions were performed with the Pyro Gold reagent kit
SPQ 96MA according to the manufacturer instructions
(Biotage, Uppsala, Sweden).
Statistical analysis
We correlated our data by using an A-Priori data mining
algorithm for tables with Unknown Values corresponding
to missing data [30]. Let T (A1, A2, ..., Ak) be a table with
attributes (columns) A1, A2, ..., Ak. Each column Ai is a
predicate (truth-value function) that assigns to every row
r (experiment) one of the three values: True, False,
Unknown. This means that Ai(r) = True/False/Unknown
indicates that Ai holds/does not hold/is unknown in the
experiment r. For example, rows may be NB samples and
columns may be RT-PCR or GI data. In this case, Ai(r) =
True (resp. False, resp. Unknown) may indicate that gene
Ai is overexpressed (resp. is not overexpressed, resp. could
not be unambiguously assigned a value) in sample r.
Datamining searches for highly related facts that consti-
tute a frequent itemset. Any datamining algorithm tries to
construct the collection Lj of all frequent itemsets S of size
j.
Definition 1
(frequent itemset). Given a positive threshold t, a frequent
itemset S of size j includes j columns Ai1, Ai2, ..., Aij such
that the ratio [Number of rows r in which (Ai1(r)
AND*Ai2(r) AND* ... AND* Aij(r)) = True]/[Number of
rows r in which (Ai1(r) AND* Ai2(r) AND* ... AND*
Aij(r)) ≠ UNKNOWN] > t.
The commutative three-valued logical conjunction AND*
is an extension of the classical logical conjunction by the
following table rows:
A B A AND* B
True Unknown Unknown
False Unknown False
Unknown Unknown Unknown
The A-priori datamining algorithm exploits the monoto-
nicity property: this in the classic two-valued logic (true/
false) implies that subsets of frequent sets are themselves
frequent. However, in the presence of Unknown Values
this notion must be slightly modified in the following
way.
Genomics of TAF13, GTF2B, NC2β, TAF12 Figure 1
Genomics of TAF13, GTF2B, NC2β, TAF12. Genomic 
position of TAF13, GTF2B, NC2β, TAF12 and corresponding 
microsatellite polymorphic markers.Molecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
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TAF13, GTF2B, NC2α, TAF12, NC2βexpression in NB samples Figure 2
TAF13, GTF2B, NC2α, TAF12, NC2βexpression in NB samples. A: RT-PCR analysis of NC2β expression in a control 
(BL8) and in NB samples. B, C, D: Diminished expression of NC2β, TAF12, TAF13 in NB samples with respect to human adult 
peripheral blood (BL). E, F: Similar expression of GTF2B and NC2α in control and NB samples.Molecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
Page 6 of 10
(page number not for citation purposes)
Definition 2
(candidate set). A set S of j columns Ai1, Ai2, ..., Aij is can-
didate if
[Number of rows r in which (Ai1(r) AND* Ai2(r) AND*
... AND* Aij(r)) = True]/[Number of rows r in which there
are NOT UNKNOWN values] >t.
Here is the pseudo-code for the A-priori data mining with
unknown values
Inizialization step:
Let C1 be the set of candidate single columns.
Let L1 be the set of columns Ai in C1 which are also fre-
quent.
Recursive step:
For each j >1
Let Cj be the set of j columns Ai1, Ai2, ..., Aij, such that
each subset of j-1 columns is in Cj-1.
Let Lj be the collection of sets in Cj that are frequent.
Since in practice very few rows have Unknown Values, the
speed-up given by the above A-priori strategy is similar to
that given by the classical two-valued logic A-priori
datamining. To establish the statistical significance of our
results, p-values were computed by using Efron multiple
hypotheses testing [31].
Results and Discussion
Based on TAF13, GTF2B, NC2β, TAF12 genomic location
and molecular functions, we considered these four GTA
genes as positional and functional candidates for involve-
ment in NB pathogenesis (see Additional file 1, Table 1
and Figure 1). As reference marker, we used the GTA pro-
Table 3: Correlation between decrease of GTA genes mRNA and NB phenotype
NC2β TAF13 TAF12
NB patients with mRNA decrease 73.6% (39/53) 48.8% (21/43) 43.2% (19/44)
NB patients with normal mRNA levels 26.4% (14/53) 51.2% (22/43) 56.8% (25/44)
p-value 0.0039 0.543 0.527
Genotype/phenotype correlation in neuroblastoma Figure 3
Genotype/phenotype correlation in neuroblastoma. A: Normal levels of the mRNAs encoding NC2β, TAF12, TAF13 
always correspond to GI absence. Low levels of these mRNA species are frequently associated with GI. B: Densitometric pat-
tern of microsatellites showing GI at the locus NC2β in a NB sample (T) and its absence in the blood (C) from the same indi-
vidual.Molecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
Page 7 of 10
(page number not for citation purposes)
tein NC2α (the molecular partner of NC2β), that is
encoded by a gene located at 11q13.3 (see Additional file
1, Table 1) [32]. Expression of these genes was analyzed
through RT – PCR in fifty eight NB biopsies (see Addi-
tional file 2, Table 1 and Figure 2). As a preliminary step,
we characterized their mRNA phenotype in ten peripheral
blood samples from normal individuals and we did not
observe significant variations of their transcription level
(Table 1, Figure 2). On the other hand, in NB we found a
clear-cut decrease (from 3 to 8 times) of the mRNAs
encoding TAF13, NC2β, TAF12 with respect to peripheral
blood from the same individuals in 49% (21/43), 74%
(39/53), 43% (19/44) samples, respectively (Figures 2
and 3). Statistical analysis demonstrated a significant pos-
itive correlation between NC2β transcripts reduction and
NB (p = 0.0039), whereas this was not obtained for TAF13
and TAF12 (Table 3). NC2β mRNA levels are significantly
decreased in both NB advanced stages III and IV (p =
0.0039); their reduction also in stage I (p = 0.0039) could
suggest a peculiar natural history of NB (Figure 4). In the
same set of samples, we did not detect any change of the
levels of the mRNAs encoding GTF2B and NC2α (Figure
2). By using at least two closely flanking microsatellite
markers for each gene, we then analyzed the genome of
the same NB samples for deletions at the loci TAF13,
GTF2B, NC2β, TAF12, NC2α (Table 2, Figures 1 and 3):
these were found in more than 60% of samples with
diminished levels of the mRNAs encoding either TAF13
(62.5%), NC2β(65%), or TAF12 (67%), but were never
detected in NB samples with normal levels of mRNA for
these three genes (Figures 3A, B, 5A). Similarly, we never
found deletions at the GTF2B and NC2α loci both in NB
biopsies as well as in controls (not shown). Due to aneu-
ploidy, we suggest that for NB as for other tumours GI
(Genomic Imbalance) may be more appropriate than
LOH (Loss of Heterozygosity). In NB samples with GI for
NC2β, we never detect it for TAF12 or TAF13 (Figure 5B):
the anticorrelation between NC2β and TAF13 reached sta-
tistical significance (p = 0.043). TAF 12 and TAF 13
seemed to show a reciprocal positive correlation since in
80% of samples GI was absent in both. Besides genomic
deletions, the reduced levels of the mRNAs encoding
NC2β, TAF12, TAF13 in NB samples could be due to: (i)
epigenetic modifications of promoter DNA, such as meth-
ylation [33]; (ii) mutations in the promoter or other regu-
latory regions [34]; (iii) increased mRNA turnover [35];
(iv) negative regulation by miRNAs [36,37]. To test the
first of these possibilities, we analyzed a panel of NB biop-
sies and NB cell lines with low levels of mRNAs for these
three genes and checked the methylation status of the 4 to
7 CpG doublets found in their bona fide promoter (see
Additional file 3, Figure 6). In general, very low or no
methylation was observed both in the tumor samples as
in the cell lines (see Additional file 3, Figure 6). We did
observe higher levels of DNA methylation in the NC2β
gene, that was however not correlated to its expression
with the exception of sample NB41 (Figures 2 and 6): this
indicates that other mechanisms, such as negative regula-
tion by microRNAs, should be considered to account for
the low levels of expression of these genes in NB [36,37].
Our data allow us to speculate on the biological role of
GTA proteins NC2, TAF12, TAF13, GTF2B. NC2 is an evo-
lutionarily conserved transcriptional regulator for which
an intriguing general role was proposed: it could repress
basal transcription in the absence of activators or alterna-
tively stimulate it in their presence [9]. Analogously to
p53 role as Guardian of the Genome, NC2 could represent
the Guardian of the Transcription Machinery and control its
GI frequency at the loci TAF13, NC2β, TAF12 Figure 5
GI frequency at the loci TAF13, NC2β, TAF12. In NB 
samples with Genomic Imbalance (GI) for NC2β, we never 
detect it for TAF12 or TAF13: the anticorrelation between 
NC2β and TAF13 reached statistical significance (p = 0.043). 
TAF 12 and TAF 13 seemed to show a reciprocal positive 
correlation since in 80% of samples GI was absent in both.
Correlation between GTA mRNA expression and NB stages Figure 4
Correlation between GTA mRNA expression and 
NB stages. A statistically significant association exists 
between NC2β mRNA decrease and NB stages III and IV (4/
39 and 17/39, respectively) (p = 0.003937). Interestingly, it 
was also found with stage I (p = 0.003922): this could suggest 
a stage-specific selection of the NC2β (-) mRNA phenotype.Molecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
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balanced functioning, performing a role as tumor sup-
pressor possibly not restricted to NB: reduced levels of the
protein could be responsible for the inappropriate activa-
tion of genes promoting cellular proliferation, thus con-
tributing to cell transformation. Its two subunits NC2α
and NC2β could perform distinct roles in the regulation
of gene expression and determination of cell phenotype:
binding of holoNC2 marks repressed promoters, while
Methylation of NC2β promoter Figure 6
Methylation of NC2β promoter. A: CpG islands upstream and downstream of NC2β, TAF12, TAF13 transcription start 
site. B: Methylation percentage of CpG sites within NC2β island. Samples with methylation levels below 10% are considered 
unmethylated: accordingly, we suggest that promoter methylation may explain the low NC2β mRNA expression only in sample 
NB41 (Figure 2). For methylation analysis of TAF12 and TAF13 promoter, (see Additional file 3).Molecular Cancer 2008, 7:52 http://www.molecular-cancer.com/content/7/1/52
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occupancy by NC2α correlates with active promoters [38].
TAF12 and TAF13 encode two small subunits of GTF2D.
TAF12 interacts directly with TBP [39]. Similar to TAF4b,
TAF6 and TAF9, it contains a histone fold domain (HFD):
the polypeptide is part of a histone-like TAF complex that
was shown to be critically important for GTF2D architec-
ture [40]. TAF13, that interacts with TBP, TAF10 and
TAF11, is associated with only a subset of GTF2D com-
plexes [39]. Reduced levels of TAF12 and TAF13 could
alter GTF2D structure and function and deregulate the
expression of different genes, such as those involved in
cell cycle control: different mutations of yTAF25 (the yeast
ortholog of TAF12) are known to induce distinct pheno-
types and affect the regulation of different subsets of genes
[41]. GTF2B is a highly conserved member of GTA [42]: it
forms a complex with GTF2D and GTF2A (the DAB com-
plex), bridging RNA polymerase II and the promoter [43].
The protein is also a target of Mediator and gene – specific
transcriptional activators [44]. Its critical molecular and
biological role could explain our failure to detect GTF2B
deletions in NB, since they would expose the cells to a
strong negative selection. A similar argument could be put
forward to explain the absence of NC2α deletions in our
dataset. Cell proliferation and specularly tumorigenesis
are very complex phenomena. Aneuploidy and GI are
common features of neoplastic genomes [45,46]. The
ensuing haploinsufficiency may cause loss of the cell abil-
ity to autonomously control its proliferation and to coor-
dinate it with that of other cells of the same organism.
Unexpected odd partners seem to be involved in the proc-
ess. Our approach has allowed us to demonstrate that
reduced expression and GI at the GTA locus NC2β is fre-
quently and specifically present in the genome of NB
tumour cells, possibly as a result of mutations of caretaker
genes involved in DNA repair or chromosomal segrega-
tion and of complex selective mechanisms [14, 46, this
paper]. The possible anticorrelation between NC2β on the
one side and TAF12 and TAF13 on the other may suggest
that these proteins could perform analogous biological
roles and as such they may reciprocally complement each
other as negative regulators of proliferation.
Conclusion
The data presented in this paper experimentally confirm
our hypothesis that at least some GTA proteins may also
be physiologically involved in the control of cell prolifer-
ation, at the same time underscoring the importance of
natural selection within complex biopathological proc-
esses [22,47]. They also suggest possible ways to exploit
molecular  omic  profiling to determine biological func-
tions and design rational anticancer therapies.
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